General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial

Springer Science and Business Media LLC - Tập 22 Số 1
Edward Franek1, Прем Пайс2, Jan Basile3, Claudia Nicolay4, Sohini Raha4, Ana Hickey4, Nadia Ahmad4, Маниге Кониг4, Hong Kan4, Hertzel C. Gerstein5
1Mossakowski Medical Research Centre, Polish Academy of Sciences and Central Clinical Hospital MSWiA, Warsaw, Poland
2St. John's Research Institute, Bangalore, India
3Medical University of South Carolina, Ralph H. Johnson VA Medical Center, Charleston, SC, USA
4Eli Lilly and Company, Indianapolis, IN, USA
5Population Health Research Institute, McMaster University, and Hamilton Health Sciences, Hamilton, ON, Canada

Tóm tắt

Abstract Background In clinical practice, anthropometric measures other than BMI are rarely assessed yet may be more predictive of cardiovascular (CV) risk. We analyzed the placebo group of the REWIND CV Outcomes Trial to compare several anthropometric measures as baseline risk factors for cardiovascular disease (CVD)-related outcomes in participants with type 2 diabetes (T2D). Methods Data from the REWIND trial placebo group (N = 4952) were analyzed. All participants had T2D, age ≥ 50 years, had either a previous CV event or CV risk factors, and a BMI of ≥ 23 kg/m2. Cox proportional hazard models were used to investigate if BMI, waist-to-hip ratio (WHR), and waist circumference (WC) were significant risk factors for major adverse CV events (MACE)-3, CVD-related mortality, all-cause mortality, and heart failure (HF) requiring hospitalization. Models were adjusted for age, sex, and additional baseline factors selected by LASSO method. Results are presented for one standard deviation increase of the respective anthropometric factor. Results Participants in the placebo group experienced 663 MACE-3 events, 346 CVD-related deaths, 592 all-cause deaths, and 226 events of HF requiring hospitalization during the median follow-up of 5.4 years. WHR and WC, but not BMI, were identified as independent risk factors of MACE-3 (hazard ratio [HR] for WHR: 1.11 [95% CI 1.03 to 1.21]; p = 0.009; HR for WC: 1.12 [95% CI 1.02 to 1.22]; p = 0.012). WC adjusted for hip circumference (HC) showed the strongest association with MACE-3 compared to WHR, WC, or BMI unadjusted for each other (HR: 1.26 [95% CI 1.09 to 1.46]; p = 0.002). Results for CVD-related mortality and all-cause mortality were similar. WC and BMI were risk factors for HF requiring hospitalization, but not WHR or WC adjusted for HC (HR for WC: 1.34 [95% CI 1.16 to 1.54]; p < 0.001; HR for BMI: 1.33 [95% CI 1.17 to 1.50]; p < 0.001). No significant interaction with sex was observed. Conclusions In this post hoc analysis of the REWIND placebo group, WHR, WC and/or WC adjusted for HC were risk factors for MACE-3, CVD-related mortality, and all-cause mortality; while BMI was only a risk factor for HF requiring hospitalization. These findings indicate the need for anthropometric measures that consider body fat distribution when assessing CV risk.

Từ khóa


Tài liệu tham khảo

Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: an Endocrine Society scientific statement. Endocr Rev. 2018;39(2):79–132.

American Diabetes Association Professional Practice Committee. 8 obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2021;45:113–24.

Snijder MB, van Dam RM, Visser M, Seidell JC. What aspects of body fat are particularly hazardous and how do we measure them? Int J Epidemiol. 2006;35(1):83–92.

Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk—a review of the literature. Eur J Clin Nutr. 2010;64(1):16–22.

Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, et al. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab. 2010;95(4):1777–85.

Yusuf S, Hawken S, Ôunpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–9.

The Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085–95.

Carmienke S, Freitag MH, Pischon T, Schlattmann P, Fankhaenel T, Goebel H, et al. General and abdominal obesity parameters and their combination in relation to mortality: a systematic review and meta-regression analysis. Eur J Clin Nutr. 2013;67(6):573–85.

Gnatiuc L, Alegre-Díaz J, Wade R, Ramirez-Reyes R, Tapia-Conyer R, Garcilazo-Ávila A, et al. General and abdominal adiposity and mortality in Mexico city. Ann Intern Med. 2019;171(6):397–405.

Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359(20):2105–20.

Flegal KM, Graubard BI. Estimates of excess deaths associated with body mass index and other anthropometric variables. Am J Clin Nutr. 2009;89(4):1213–9.

Medina-Inojosa JR, Batsis JA, Supervia M, Somers VK, Thomas RJ, Jenkins S, et al. Relation of waist-hip ratio to long-term cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2018;121(8):903–9.

Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Waist-to-hip ratio and mortality in heart failure. Eur J Heart Fail. 2018;20(9):1269–77.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Design and baseline characteristics of participants in the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42–9.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.

Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B. 1996;58(1):267–88.

Belsey DA, Kuh E, Welsch RE. Regression diagnostics: Identifying influential data and sources of collinearity. New York: John Wiley & Sons; 1980.

Staiano AE, Bouchard C, Katzmarzyk PT. BMI-specific waist circumference thresholds to discriminate elevated cardiometabolic risk in White and African American adults. Obes Facts. 2013;6(4):317–24.

Doehner W, Gerstein HC, Ried J, Jung H, Asbrand C, Hess S, et al. Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. Eur Heart J. 2020;41(28):2668–77.

Lamelas P, Schwalm JD, Leong D, Jolly S, Mehta S, Bangdiwala S, et al. Varying effects of body mass index and mortality in different risk groups. Am J Cardiol. 2018;122(7):1155–60.

Piepoli MF, Corrà U, Veglia F, Bonomi A, Salvioni E, Cattadori G, et al. Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI score research group. Eur J Heart Fail. 2016;18(5):545–53.

Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–13.

Glogner S, Rosengren A, Olsson M, Gudbjörnsdottir S, Svensson A-M, Lind M. The association between BMI and hospitalization for heart failure in 83 021 persons with type 2 diabetes: a population-based study from the Swedish national diabetes registry. Diabet Med. 2014;31(5):586–94.

Chaney E, Shaw A. Pathophysiology of Fluid Retention in Heart Failure. Contrib Nephrol. 2010;164:46–53.

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140(11):e596-646.

Lopez-Lopez JP, Cohen DD, Ney-Salazar D, Martinez D, Otero J, Gomez-Arbelaez D, et al. The prediction of metabolic syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone. Cardiovasc Diabetol. 2021;20(1):68.

Parente EB, Harjutsalo V, Forsblom C, Groop P-H, on behalf of The FinnDiane Study Group. The impact of central obesity on the risk of hospitalization or death due to heart failure in type 1 diabetes a 16-year cohort study. Cardiovasc Diabetol. 2021;20(1):153.

Ichikawa R, Daimon M, Miyazaki T, Kawata T, Miyazaki S, Maruyama M, et al. Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12(1):38.

Hazewinkel A-D, Richmond RC, Wade KH, Dixon P. Mendelian randomization analysis of the causal impact of body mass index and waist-hip ratio on rates of hospital admission. Econ Hum Biol. 2022;44:101088.

Selvaraj S, Martinez EE, Aguilar FG, Kim K-YA, Peng J, Sha J, et al. Association of central adiposity with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network study. Circ Cardiovasc Imaging. 2016. https://doi.org/10.1161/CIRCIMAGING.115.004396.

Piché M-E, Poirier P, Lemieux I, Després J-P. Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update. Prog Cardiovasc Dis. 2018;61(2):103–13.

Ke J-F, Wang J-W, Lu J-X, Zhang Z-H, Liu Y, Li L-X. Waist-to-height ratio has a stronger association with cardiovascular risks than waist circumference, waist-hip ratio and body mass index in type 2 diabetes. Diabetes Res Clin Pract. 2022;183:109151.

Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394–405.

Bando Y, Kanehara H, Aoki K, Hisada A, Toya D, Tanaka N. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients. J Diabetes Investig. 2012;3(2):170–4.

American Diabetes Association. 10 cardiovascular disease and risk management: standards of medical care in diabetes 2022. Diabetes Care. 2021;45:144-74. https://doi.org/10.2337/dc22-S010

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 22 Số 1

Thông tin tác giả